1887
  1. Home
  2. Eurosurveillance
  3. Volume 26, Issue 49, 09/Dec/2021
  4. Article
Rapid communication Open Access
Like 0
Download

Abstract

Several factors may account for the recent increased spread of the SARS-CoV-2 Delta sub-lineage AY.4.2 in the United Kingdom, Romania, Poland, and Denmark. We evaluated the sensitivity of AY.4.2 to neutralisation by sera from 30 Comirnaty (BNT162b2 mRNA) vaccine recipients in Denmark in November 2021. AY.4.2 neutralisation was comparable to other circulating Delta lineages or sub-lineages. Conversely, the less prevalent B.1.617.2 with E484K showed a significant more than 4-fold reduction in neutralisation that warrants surveillance of strains with the acquired E484K mutation.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2021.26.49.2101059
2021-12-09
2024-11-21
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2021.26.49.2101059
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/26/49/eurosurv-26-49-3.html?itemId=/content/10.2807/1560-7917.ES.2021.26.49.2101059&mimeType=html&fmt=ahah

References

  1. United Kingdom Health Security Agency (UKHSA). SARS-CoV-2 variants of concern and variants under investigation in England. Technical Briefing 26. London: UKHSA; 2021. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1028113/Technical_Briefing_26.pdf
  2. United Kingdom Health Security Agency (UKHSA). SARS-CoV-2 variants of concern and variants under investigation in England. Technical Briefing 29. London: UKHSA; 2021. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1036501/Technical_Briefing_29_published_26_November_2021.pdf
  3. World Health Organization (WHO). COVID-19 Weekly Epidemiological Update - edition 63. Geneva: WHO; 2021. Available from: https://apps.who.int/iris/handle/10665/347449
  4. Latif AA, Mullen JL, Alkuzweny M, Tsueng G, Cano M, Haag E, et al. AY.4.2 Lineage Report. Outbreak.info. [Accessed: 26 Nov 2021]. Available from: https://outbreak.info/situation-reports?pango=AY.4.2&loc=IND&loc=GBR&loc=USA&selected
  5. Chen RE, Zhang X, Case JB, Winkler ES, Liu Y, VanBlargan LA, et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat Med. 2021;27(4):717-26.  https://doi.org/10.1038/s41591-021-01294-w  PMID: 33664494 
  6. Liu Z, VanBlargan LA, Bloyet L-M, Rothlauf PW, Chen RE, Stumpf S, et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe. 2021;29(3):477-488.e4.  https://doi.org/10.1016/j.chom.2021.01.014  PMID: 33535027 
  7. United Kingdom Health Security Agency (UKHSA). SARS-CoV-2 variants of concern and variants under investigation in England. Technical Briefing 27. London: UKHSA; 2021. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1029715/technical-briefing-27.pdf
  8. Baj A, Novazzi F, Pasciuta R, Genoni A, Ferrante FD, Valli M, et al. Breakthrough infections of E484K-harboring SARS-CoV-2 Delta variant, Lombardy, Italy. Emerg Infect Dis. 2021;27(12):3180-2.  https://doi.org/10.3201/eid2712.211792  PMID: 34499599 
  9. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-15.  https://doi.org/10.1056/NEJMoa2034577  PMID: 33301246 
  10. GeurtsvanKessel CH, Okba NMA, Igloi Z, Bogers S, Embregts CWE, Laksono BM, et al. An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. Nat Commun. 2020;11(1):3436.  https://doi.org/10.1038/s41467-020-17317-y  PMID: 32632160 
  11. Lassaunière R, Frische A, Harboe ZB, Nielsen ACY, Fomsgaard A, Krogfelt KA, et al. Evaluation of nine commercial SARS-CoV-2 immunoassays. medRxiv. 2020:2020.04.09.20056325. Preprint. 10.1101/2020.04.09.20056325
  12. World Health Organization (WHO). Manual for the laboratory diagnosis and virological surveillance of influenza. Geneva: WHO; 2011. Available from: https://apps.who.int/iris/handle/10665/44518
  13. Nguyen D, Simmonds P, Steenhuis M, Wouters E, Desmecht D, Garigliany M, et al. SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data. Euro Surveill. 2021;26(27):2100568.  https://doi.org/10.2807/1560-7917.ES.2021.26.27.2100568  PMID: 34240697 
  14. Hodcroft EB, Zuber M, Nadeau S, Vaughan TG, Crawford KHD, Althaus CL, et al. Spread of a SARS-CoV-2 variant through Europe in the summer of 2020. Nature. 2021;595(7869):707-12.  https://doi.org/10.1038/s41586-021-03677-y  PMID: 34098568 
  15. Latif AA, Mullen JL, Alkuzweny M, Tsueng G, Cano M, Haag E, et al. S:E484K Mutation Report. Outbreak.info. [Accessed: 10 Nov 2021]. Available at: https://outbreak.info/situation-reports?pango&muts=S%3AE484K
  16. Jangra S, Ye C, Rathnasinghe R, Stadlbauer D, Krammer F, Simon V, et al. SARS-CoV-2 spike E484K mutation reduces antibody neutralisation. Lancet Microbe. 2021;2(7):e283-4.  https://doi.org/10.1016/S2666-5247(21)00068-9  PMID: 33846703 
  17. Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021;593(7857):130-5.  https://doi.org/10.1038/s41586-021-03398-2  PMID: 33684923 
  18. Github.com. Issue # 361. Proposal to split B.1.1.529 to incorporate a newly characterised sibling lineage. GitHub Repository. GitHub. [Accessed: 8 Dec 2021]. Available from: https://github.com/cov-lineages/pango-designation/issues/361
Neutralisation of the SARS-CoV-2 Delta variant sub-lineages AY.4.2 and B.1.617.2 with the mutation E484K by Comirnaty (BNT162b2 mRNA) vaccine-elicited sera, Denmark, 1 to 26 November 2021
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Ria+Lassauni%C3%A8re&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Lassaunière Ria</a>, <a href="/search?value1=Charlotta+Polacek&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Polacek Charlotta</a>, <a href="/search?value1=Jannik+Fonager&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Fonager Jannik</a>, <a href="/search?value1=Marc+Bennedb%C3%A6k&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Bennedbæk Marc</a>, <a href="/search?value1=Lasse+Boding&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Boding Lasse</a>, <a href="/search?value1=Morten+Rasmussen&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Rasmussen Morten</a>, <a href="/search?value1=Anders+Fomsgaard&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Fomsgaard Anders</a></span>. Neutralisation of the SARS-CoV-2 Delta variant sub-lineages AY.4.2 and B.1.617.2 with the mutation E484K by Comirnaty (BNT162b2 mRNA) vaccine-elicited sera, Denmark, 1 to 26 November 2021. <a href="/content/ecdc">Euro Surveill.</a> 2021;26(49):pii=2101059. <a href="https://doi.org/10.2807/1560-7917.ES.2021.26.49.2101059" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2021.26.49.2101059</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 11 Nov 2021;&nbsp;&nbsp; <span class="generated">Accepted</span>: 08 Dec 2021 </span> </p>
/content/10.2807/1560-7917.ES.2021.26.49.2101059
/content/10.2807/1560-7917.ES.2021.26.49.2101059
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error